Immune checkpoint inhibitors (ICIs) block the inhibitory effects of cancer cells on the immune cells, which up-regulates immunologic tumor control.1 This, in turn, can lead to autoimmune inflammation of other organ systems, collectively called immune-related adverse events (irAEs).2-4 These adverse events are distinct in mechanism and management from those of other systemic anti-cancer therapies.5-7 While lower-grade irAEs are usually managed with temporary treatment interruption or...
